Worth reading
73In focus
Scored from 4 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
-1977
¥ million (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Presentation materials for financial resultsFirst quarter of the fiscal year ending December 20267 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥5,526 million
Operating profit¥-2,749 million
Net income¥-3,376 million
Selling, general and administrative expenses¥5,459 million
Results for the three months of the current quarter
Revenue
¥5,526 million
Operating profit
¥-2,749 million
Profit before tax
¥-3,187 million
Profit for the period
¥-3,376 million
Profit attributable to owners of the parent
¥-2,127 million
Full-year earnings forecast
Consolidated revenue
¥27,158 million
Pharmaceutical business revenue
¥16,000 million
Drug discovery business revenue
¥544 million
Medtech business revenue
¥9,674 million
Other businesses revenue
¥940 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
- Increase in revenue¥206 million
- Marketing expenses, including preparations for the launch of F351¥539 million
- Share-based compensation expense¥415 million
- Advisory fees related to making Cullgen a wholly owned subsidiary¥400 million
- R&D expenses ahead of the U.S. IND application for F351¥160 million
- Corporate fixed costs¥-157 million
- Loss on valuation of equity securities¥-195 million
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
USD/JPY155
CNY/JPY21
New initiatives
- Preparations for the launch of F351 and advancement of the NDA review in China
- Gyre Therapeutics' acquisition of Cullgen as a wholly owned subsidiary and integration of the two companies
- Application for approval and rollout of BAB's proprietary branded strategic products
- OsDerma's expansion into the medical aesthetics market
Key KPIsA metric the company considers important as a management benchmark.
- Number of companies26 companies
- Number of employees990 People
- Development pipeline and marketed products23 Engagements
- Sales network locations in China3,000 Location
- Number of medical representatives in China400 People
- Medtech business revenue¥1,518 millionYear on year against the same period last year+¥148 million
- BAB revenueYear on year against the same period last year+22%
Segment results
Pharmaceutical business
Revenue
¥3,547 million
Operating profit
¥-40 million
Revenue growth
¥232 million
Year-on-year operating profit growth
¥-850 million
Drug Discovery Business
Revenue
¥172 million
Operating profit
¥-1,048 million
Revenue growth
¥-181 million
Year-on-year operating profit growth
¥90 million
MedTech Business
Revenue
¥1,518 million
Operating profit
¥-246 million
Revenue growth
¥148 million
Year-on-year operating profit growth
¥-491 million
Other Businesses
Revenue
¥281 million
Operating profit
¥-1,423 million
Revenue growth
¥2 million
Year-on-year operating profit growth
¥-525 million
Market Size / Share
- Radiation-induced lung injury (RILI) in China$490 million (approximately ¥77 billion) in 2032Number of patients120,000 patients in 2032
- China's medical aesthetics market¥7,183.6 billion in 2023
Number of employees
Number of Employees990 People
Reference dateEnd of December 2025
| Item | Details |
|---|---|
| Document type | Presentation materials for financial results |
| Fiscal Period Covered | First quarter of the fiscal year ending December 2026 |
| Net Sales | ¥5,526 million |
| Operating profit | ¥-2,749 million |
| Net income | ¥-3,376 million |
| Selling, general and administrative expenses | ¥5,459 million |
| Results for the three months of the current quarter | Revenue ¥5,526 million / Operating profit ¥-2,749 million / Profit before tax ¥-3,187 million / Profit for the period ¥-3,376 million / Profit attributable to owners of the parent ¥-2,127 million |
| Full-year earnings forecast | Consolidated revenue ¥27,158 million / Pharmaceutical business revenue ¥16,000 million / Drug discovery business revenue ¥544 million / Medtech business revenue ¥9,674 million / Other businesses revenue ¥940 million / Operating profit Not disclosed / Profit before tax Not disclosed / Net income Not disclosed |
| Segment results | Pharmaceutical business Revenue ¥3,547 million / Operating profit ¥-40 million / Revenue growth ¥232 million / Year-on-year operating profit growth ¥-850 million / Drug Discovery Business Revenue ¥172 million / Operating profit ¥-1,048 million / Revenue growth ¥-181 million / Year-on-year operating profit growth ¥90 million / MedTech Business Revenue ¥1,518 million / Operating profit ¥-246 million / Revenue growth ¥148 million / Year-on-year operating profit growth ¥-491 million / Other Businesses Revenue ¥281 million / Operating profit ¥-1,423 million / Revenue growth ¥2 million / Year-on-year operating profit growth ¥-525 million |
| Breakdown of Factors Affecting the Change | Factors Increase in revenue / Amount ¥206 million, Factors Marketing expenses, including preparations for the launch of F351 / Amount ¥539 million, Factors Share-based compensation expense / Amount ¥415 million, Factors Advisory fees related to making Cullgen a wholly owned subsidiary / Amount ¥400 million, Factors R&D expenses ahead of the U.S. IND application for F351 / Amount ¥160 million, Factors Corporate fixed costs / Amount ¥-157 million, Factors Loss on valuation of equity securities / Amount ¥-195 million |
| Key KPIs | Indicator name Number of companies / Value 26 companies / Year on year against the same period last year Not disclosed, Indicator name Number of employees / Value 990 People / Year on year against the same period last year Not disclosed, Indicator name Development pipeline and marketed products / Value 23 Engagements / Year on year against the same period last year Not disclosed, Indicator name Sales network locations in China / Value 3,000 Location / Year on year against the same period last year Not disclosed, Indicator name Number of medical representatives in China / Value 400 People / Year on year against the same period last year Not disclosed, Indicator name Medtech business revenue / Value ¥1,518 million / Year on year against the same period last year +¥148 million, Indicator name BAB revenue / Value Not disclosed / Year on year against the same period last year +22% |
| Number of employees | Number of Employees 990 People / Reference date End of December 2025 / Change during the period Not disclosed / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | USD/JPY 155 / CNY/JPY 21 |
| Market Size / Share | Subject Radiation-induced lung injury (RILI) in China / Market Size $490 million (approximately ¥77 billion) in 2032 / Number of patients 120,000 patients in 2032, Subject China's medical aesthetics market / Market Size ¥7,183.6 billion in 2023 |
| New initiatives | Preparations for the launch of F351 and advancement of the NDA review in China, Gyre Therapeutics' acquisition of Cullgen as a wholly owned subsidiary and integration of the two companies, Application for approval and rollout of BAB's proprietary branded strategic products, OsDerma's expansion into the medical aesthetics market |
Items this document does not state (16)
Ordinary incomeGross Profit MarginOperating profit marginProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue was driven by the expansion of the medtech business through newly consolidated subsidiary ZOO LABO, in addition to the solid performance of the pharmaceutical business. The deterioration in operating profit was attributable to marketing investments related to preparations for the launch of F351, Gyre's share-based compensation expense, costs related to making Cullgen a wholly owned subsidiary, and increased R&D expenses ahead of the U.S. IND application for F351.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.